WARNING
Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs. (See "DOSAGE AND ADMINISTRATION".)
|
| |
SUMMARY
FUROSEMIDE
INJECTION, USP
10 mg/mL
Furosemide is a diuretic which is an anthranilic acid derivative.
Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.
Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired.
Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema.
If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral furosemide as soon as practical.
|
NEWS HIGHLIGHTS
Published Studies Related to Furosemide Injection (Furosemide)
Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: A double blind randomized controlled trial. [2009.12.26]
OBJECTIVE:: To study the potential beneficial role of furosemide in resolving renal failure after hemofiltration in mechanically ventilated critically ill patients... CONCLUSION:: Furosemide by continuous infusion in the recovery phase of hemofiltration-dependent acute kidney failure did increase urinary volume and sodium excretion but did not lead to a shorter duration of renal failure or more frequent renal recovery.
Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. [2009.10]
BACKGROUND: Contrast-induced nephropathy is common in patients with coronary angiography. Mechanistically, forced euvolemic diuresis with mannitol and furosemide ought to prevent contrast-induced nephropathy. Our objectives are to: (1) undertake a randomized trial testing this hypothesis, and (2) conduct a meta-analysis of our findings with 2 earlier studies... CONCLUSIONS: Forced euvolemic diuresis led to a significantly increased risk of contrast-induced nephropathy. This strategy should be abandoned, and our results suggest that oral furosemide therapy perhaps should be held before angiography.
TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. [2009.08]
Loop diuretics, such as torasemide and furosemide, are important agents in the treatment of chronic heart failure. Beneficial effects of torasemide immediate-release formulation beyond diuresis have been documented as the ability of this compound to inhibit myocardial synthesis and deposition of collagen type I in patients with chronic heart failure.
Efficacy of furosemide for prevention of exercise-induced pulmonary hemorrhage in Thoroughbred racehorses. [2009.07.01]
OBJECTIVE: To evaluate the efficacy of furosemide for prevention of exercise-induced pulmonary hemorrhage (EIPH) in Thoroughbred racehorses under typical racing conditions...
Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial. [2009.02]
OBJECTIVE: To study the potential beneficial role of furosemide in resolving renal failure after hemofiltration in mechanically ventilated critically ill patients... CONCLUSION: Furosemide by continuous infusion in the recovery phase of hemofiltration-dependent acute kidney failure did increase urinary volume and sodium excretion but did not lead to a shorter duration of renal failure or more frequent renal recovery.
Clinical Trials Related to Furosemide Injection (Furosemide)
Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure [Completed]
The purpose of this study is to determine whether continuing or discontinuing furosemide (a
diuretic) on the day of elective noncardiac surgery for those who take furosemide on a
chronic basis, causes more intraoperative hypotension (low blood pressure) during surgery.
Our hypothesis is that the usual practice of continuing furosemide on the day of surgery
would contribute to more hypotension during surgery than discontinuing furosemide.
The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride [Active, not recruiting]
Thiazolidinedionederivates (TZD’s) are Peroxisome-Proliferator-Activated-Receptor-γ agonists
(PPARγ-agonists) and enhance insulin sensitivity. One of the side effects, however, is the
fact that subjects treated with these drugs seem to be more prone to fluid retention. The
precise mechanism of rosiglitazone-related fluid retention is unknown, but it is clear that
either primary or secondary renal sodium retention is part of the mechanism. Furthermore in
observational studies, TZD-related oedema seems to be resistant to loop diuretic therapy. The
recent finding that rosiglitazone induces upregulation of the epithelial sodium channel
(ENaC) in the kidney could be the explanation for TZD-related fluid retention and the
observed resistance to loop diuretics. In the present human in-vivo study the following
hypothesis will be tested:
Rosiglitazone treatment stimulates the activity of ENaC in the distal nephron, which enhances
the natriuretic effect of amiloride and decreases the natriuretic effect of furosemide in
parallel.
Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSS [Completed]
This is a randomized, open-label, three-way crossover design study with 3 treatment
groups: TREATMENT A: Furosemide;TREATMENT B: Nesiritide administered IV bolus, followed by an
infusion for 6 hours;TREATMENT C: Treatment B for at least 15 minutes, then administration
of treatment AAll sequences involving both furosemide and nesiritide had the nesiritide
infusion started first, at least 15 minutes before furosemide was administered. Each
treatment will be administered according to 1 of 6 sequences to which patients are
randomized. Patients will remain in the Clinical Research Unit for 7 days, with treatments
administered on Days 2, 4, and 6, with equilibrium (rest) days on Days 1, 3, and 5. All
patients will be followed for safety throughout the treatment phase, and by telephone between
7 and 14 days after they are discharged from the Clinical Research Unit.
Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients [Completed]
to assess the efficacy of inhaled furosemide in mustard gas exposed patients with acute
respiratory failure
Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure [Recruiting]
The purpose of this prospective, randomized, open-label study is to compare two diuretic
strategies in patients with acute decompensated heart failure (ADHF): the addition of an
oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to
transition from IVB to continuous infusion (CI) loop diuretic.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Furosemide Injection has an overall score of 2. The effectiveness score is 2 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| | Furosemide Injection review by care giver of 90 year old female patient | | | Rating |
| Overall rating: | |   |
| Effectiveness: | | Ineffective |
| Side effects: | | No Side Effects | | |
Treatment Info |
| Condition / reason: | | CHF |
| Dosage & duration: | | varied (dosage frequency: as needed) for the period of 2 weeks |
| Other conditions: | | atrial fibrillation |
| Other drugs taken: | | heart medications, potassium | | |
Reported Results |
| Benefits: | | The IV form was effective in removing excess fluid. The oral form did not. |
| Side effects: | | The oral form did not remove the fluid. |
| Comments: | | Patient received IV form in hospital and fluid came off quickly and effectively. Oral form, which she was sent home on, did not work and she ended up back in the hospital within 24 hours. One of the doctors later admitted that there was something about the oral form that caused it to be ineffective in certain situations. |
|
|
|
Page last updated: 2009-10-20
|
